HOME >> BIOLOGY >> NEWS
UB Researcher Developing Method That Employs "Evolution" To Identify New Drug Leads

atorial chemistry," he said.

The new method synthesizes many different compounds at once in complex mixtures. Then, because of the presence of a molecular target, its components naturally will evolve into the best candidate molecules.

"This method employs basic principles of Darwinian evolution," said Eliseev. "It's survival of the fittest. Our method increases the amount of the desirable compounds and decreases the amount of the undesirable ones."

Unlike other combinatorial methods, the UB method works by using molecular recognition -- the ability of molecules to bind to a target -- to simultaneously form and screen mixtures of many chemicals for the best ones.

During a stage the scientists call equilibration, or variation, the components of these mixtures are manipulated by the presence of the molecular target to "evolve" higher fractions of the best compounds.

"Our mixture circulates through two chromatographic columns," explained Eliseev. "In one of them, which we call the selection chamber, the effective components bind to the immobilized target compound. In the other one, the remaining mixture is brought to an equilibrium, where the mixture regenerates the fraction of the effective binders it just lost."

In the same way that natural evolution plays out over the course of many generations, chemical evolution occurs over the course of many repeated cycles during which the chemical library continually reforms itself, evolving a much larger subset of effective components.

These components then are isolated from the mixture and analyzed to identify potential drug leads.

The method has been proven in a model system.

The UB scientists are using it to develop drug candidates against the enzyme pepsin, which is found in the stomach and involved in the formation of ulcers.


'"/>

Contact: Ellen Goldbaum
goldbaum@newsb.buffalo.edu
716-645-2626
University at Buffalo
22-May-1998


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
(Date:10/22/2014)... , Oct. 22, 2014 New test ... the in vitro diagnostic (IVD) test industry, especially as ... healthcare market researcher listed more than 25 testing innovations ... be the future of IVD products. Kalorama details the new ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: